Analysts Issue Forecasts for Surmodics Q3 Earnings

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Analysts at Barrington Research issued their Q3 2025 earnings per share estimates for Surmodics in a report released on Thursday, May 1st. Barrington Research analyst M. Petusky anticipates that the company will post earnings of ($0.21) per share for the quarter. The consensus estimate for Surmodics' current full-year earnings is $0.20 per share. Barrington Research also issued estimates for Surmodics' Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.57) EPS, Q1 2026 earnings at ($0.18) EPS and FY2026 earnings at ($0.09) EPS.

A number of other research analysts have also recently commented on the company. Needham & Company LLC reiterated a "hold" rating on shares of Surmodics in a report on Wednesday, April 30th. Lake Street Capital upgraded Surmodics from a "hold" rating to a "buy" rating and set a $43.00 price target for the company in a report on Friday, March 7th. Finally, StockNews.com started coverage on shares of Surmodics in a report on Monday, February 3rd. They issued a "hold" rating on the stock. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $43.00.

Surmodics Trading Down 0.4 %

Shares of Surmodics stock traded down $0.12 during mid-day trading on Monday, hitting $27.09. The stock had a trading volume of 10,327 shares, compared to its average volume of 211,910. The firm has a 50-day moving average of $28.94 and a two-hundred day moving average of $34.60. The firm has a market cap of $387.36 million, a P/E ratio of -26.82 and a beta of 1.32. The company has a quick ratio of 4.29, a current ratio of 5.45 and a debt-to-equity ratio of 0.26. Surmodics has a 12-month low of $26.00 and a 12-month high of $42.44.

Surmodics (NASDAQ:SRDX - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.07). Surmodics had a negative net margin of 11.48% and a negative return on equity of 4.39%. The firm had revenue of $28.09 million during the quarter, compared to analysts' expectations of $32.23 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SRDX. Principal Financial Group Inc. purchased a new stake in shares of Surmodics during the third quarter worth $1,190,000. JPMorgan Chase & Co. increased its holdings in Surmodics by 192.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 42,470 shares of the company's stock worth $1,647,000 after purchasing an additional 27,960 shares during the period. Barclays PLC raised its position in Surmodics by 16.0% in the 3rd quarter. Barclays PLC now owns 88,750 shares of the company's stock valued at $3,443,000 after purchasing an additional 12,271 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Surmodics by 22.1% in the 4th quarter. SG Americas Securities LLC now owns 6,940 shares of the company's stock valued at $275,000 after buying an additional 1,255 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in shares of Surmodics by 165.3% during the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 30,000 shares of the company's stock worth $1,188,000 after buying an additional 18,692 shares in the last quarter. Hedge funds and other institutional investors own 96.63% of the company's stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).